Combined anti-angiogenic therapy targeting PDGF and vegf receptors lowers the interstitial fluid pressure in a murine experimental carcinoma

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Kłosowska Wardȩga, Agnieszka ^a   Hasumi, Yoko ^a   Burmakin, Mikhail ^a   Åhgren, Aive ^a   Stuhr, Linda ^b   Moen, Ingrid ^b   Reed, Rolf K ^b   Rubin, Kristofer ^a   Hellberg, Carina ^a   Heldin, Carl Henrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB; ZK 22584; ANGIOGENESIS INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVITY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TISSUE PRESSURE; TUMOR VASCULARIZATION; ANIMAL; BLOOD VOLUME; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; EXTRACELLULAR FLUID; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PERICYTE; PRESSURE; TUMOR CELL LINE; VASCULARIZATION;

MURINAE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOOD VOLUME; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; EXTRACELLULAR FLUID; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PRESSURE; PROTEIN KINASE INHIBITORS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 77949534041     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008149     Document Type: Article

References (27)

1. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
2. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8: 464-478.
3. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
4. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, et al. (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13: 3942-3950.
5. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147.
6. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, et al. (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934.
7. Rodt SA, Ahlen K, Berg A, Rubin K, Reed RK (1996) A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol 495: 193-200.
8. Liden A, Berg A, Nedrebo T, Reed RK, Rubin K (2006) Platelet-derived growth factor BB-mediated normalization of dermal interstitial fluid pressure after mast cell degranulation depends on beta3 but not beta1 integrins. Circ Res 98: 635-641.
9. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, et al. (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570.
10. Salnikov AV, Heldin NE, Stuhr LB, Wiig H, Gerber H, et al. (2006) Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer 119: 2795-2802.
11. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, et al. (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62: 5476-5484.
12. Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, et al. (2003) STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 9: 3779-3787.
13. Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, et al. (2007) Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121: 2606-2614.
14. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, et al. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160: 985-1000.
15. Oldberg A, Kalamajski S, Salnikov AV, Stuhr L, Morgelin M, et al. (2007) Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci USA 104: 13966-13971.
16. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502.
17. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, et al. (2008) Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 599: 44-53.
18. Jain RK (2008) Taming vessels to treat cancer. Sci Am 298: 56-63.
19. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, et al. (2000) PTK787/ ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189.
20. Rubin K, Sjoquist M, Gustafsson AM, Isaksson B, Salvessen G, et al. (2000) Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA. Int J Cancer 86: 636-643.
21. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, et al. (2003) Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. Faseb J 17: 1756-1758.
22. Levick JR (1987) Flow through interstitium and other fibrous matrices. Q J Exp Physiol 72: 409-437.
23. Jain RK (1991) Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol 60: 85-100.
24. Ain KB, Taylor KD (1994) Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 78: 1097-1102.
25. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, et al. (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93: 4331-4341.
26. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, et al. (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 22: 195-201.
27. Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, et al. (2003) Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4: 31-39.